WuXi Biologics outlicensed global rights for ... bringing the total for the B round to $131 million. Immune-Onc is a Palo Alto, CA-Hangzhou company that is developing novel checkpoint inhibitors ...

US-based Candid Therapeutics has signed another T-cell engager (TCE) partnership, this time with Chinese biotech WuXi Biologics for the global rights to a preclinical asset. Under the deal ...

Shares of WuXi AppTec and WuXi Biologics surged in Hong Kong on Friday, following a report that the two firms are looking to divest some of their operations in the wake of new United States ...

SHANGHAI, Oct. 11, 2022 /CNW/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem BioPharma, a biotech ...

On June 20, no-moat-rated WuXi Biologics 02269 held an investor conference. According to media reports, management said that interim revenue growth will likely be in the low teens year on year and ...

(Reuters) - An influential Democratic U.S. congressman said on Friday that he will vote against legislation that would restrict business with China's WuXi Biologics, BGI and other biotech companies on ...

Wuxi Biologics, China’s largest biologic drugs services company, is in talks to sign contracts for the development of three potential vaccinations, in a bid to grab a slice of the nation’s ...